Individualizing insulin therapy for optimum glycemic control

Patient Care

Volumn 35, Issue 1, 2001, Pages 35-47

  Brown, Anne B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0038968037     PISSN: 0031305X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;324:381-389.
2. Holleman F, Schmitt H, Rottiers R, et al. Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. The Benelux-UK Insulin Lispro Study Group. Diabetes Care. 1997;20: 1827-1832.
3. Gale EA. A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with Type 1 diabetes on intensified insulin therapy. The UK Trial Group. Diabet Med. 2000;17:209-214.
4. Feinglos MN, Thacker CH, English J, et al. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes. Diabetes Care. 1997;20:1539-1542.
5. American Diabetes Association. Positon statement: Insulin administration. Diabetes Care. 2000;23(suppl 1). No. S86. Available at: http://journal. diabetes.org/FullText/Supplements/DiabetesCare/Supplement100/s86.htm. Accessed July 5, 2000.
6. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-857.
7. American Diabetes Association. Position Statement: Implications of the Diabetes Control and Complications Trial. Diabetes Care. 2000;23(suppl 1). No. S24. Available at: http://journal.diabetes.org/FullText/Supplements/ Diabetes Care/Supplement100/s24.htm. Accessed July 5, 2000.